David Cauvi, Ph.D.

David Cauvi, Ph.D.


New Therapeutic Target for Lupus
David Cauvi, Ph.D.

The Scripps Research Institute
La Jolla, CA
Decay accelerating factor and systemic autoimmunity

Systemic lupus erythematosus (SLE or lupus) is a devastating chronic autoimmune disease affecting multiple organ systems and characterized by a broad array of antibodies. Dr. David Cauvi’s laboratory has identified that a protein called decay accelerating factor (DAF), is increased in lupus-resistant mice. Dr. Cauvi will test whether an elevated level of DAF reduces the development of SLE by treating lupus-prone mice with DAF. At the completion of these experiments, Dr. Cauvi hopes to discover whether or not DAF plays a protective role in the development of SLE. If so, this provides a new target for therapeutic intervention, not only for SLE but for other autoimmune diseases, as well.

Article Author
Arthritis National Research Foundation

The Arthritis National Research Foundation's mission is to provide initial research funding to brilliant, investigative scientists with new ideas to cure arthritis and related autoimmune diseases. Writing articles about the patients affected and the science being done to find a cure shows why we need to come together to #CureArthritis!

No Comments

Sorry, the comment form is closed at this time.